Testing statins to treat low-risk blood disorders with abnormal blood counts
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 trial studies whether a statin medicine can help people with CCUS (a bone-marrow condition with abnormal genetic mutations) or lower-risk MDS (a blood disorder) that causes persistent low blood counts. It aims to see if statins can improve blood-related outcomes while keeping you safe from side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either CCUS or lower-risk MDS, confirmed by specific gene mutation results and blood test patterns
- Your low blood counts have lasted at least 6 months (low hemoglobin, low white blood cells, and/or low platelets)
- You do not need blood transfusions to manage your condition (transfusion independent)
- You are 18 years or older and can understand and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This trial tests an investigational drug called roxadustat to see if it can help people with a certain type of low-risk MDS who need frequent red blood cell transfusions. It's for patients who haven't responded to other anemia treatments.
This trial tests whether a supplement called nicotinamide riboside can help people with a blood disorder called MDS (myelodysplastic syndrome) or early warning signs of it. The supplement is meant to support your bone marrow's ability to make healthy blood cells.
Hear when a new Clonal Cytopenia of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.